OP0135 SAFETY AND EFFICACY OF SUBCUTANEOUS BELIMUMAB AND INTRAVENOUS RITUXIMAB COMBINATION IN PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME: A PHASE 2, RANDOMISED, PLACEBO-CONTROLLED 68-WEEK STUDY
Xavier Mariette, Chiara Baldini, Francesca Barone, Hendrika Bootsma, Karl J. Clark, Salvatore De Vita, Karoline Lerang, Prafull Mistry, Frédéric Morin, Rajesh Punwaney, Raphaèle Séror, Paul Van Daele, André van Maurik, Nicolas Wisniacki, David A. Roth
Topics & Concepts
MedicineRituximabBelimumabClinical endpointInternal medicineB-cell activating factorPlaceboPopulationAdverse effectGastroenterologyPhases of clinical researchImmunologyRandomized controlled trialClinical trialAntibodyB cellLymphomaPathologyAlternative medicineEnvironmental healthSalivary Gland Disorders and FunctionsSalivary Gland Tumors Diagnosis and TreatmentSystemic Sclerosis and Related Diseases